C4 Therapeutics Ownership | Who Owns C4 Therapeutics?
C4 Therapeutics Ownership Summary
C4 Therapeutics is owned by 69.58% institutional investors, 1.13% insiders, and 29.29% retail investors. Morgan stanley is the largest institutional shareholder, holding 10.94% of CCCC shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.01% of its assets in C4 Therapeutics shares.
CCCC Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | C4 Therapeutics | 69.58% | 1.13% | 29.29% |
| Sector | Healthcare Stocks | 35.56% | 12.08% | 52.36% |
| Industry | Biotech Stocks | 35.43% | 12.01% | 52.56% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Morgan stanley | 9.07M | 10.94% | $23.86M |
| Ra capital management | 8.00M | 9.65% | $21.04M |
| Bain capital life sciences investors | 7.17M | 8.65% | $18.86M |
| Lynx1 capital management lp | 7.00M | 8.44% | $18.41M |
| Blackrock | 4.55M | 6.61% | $21.03M |
| Blackrock funding, inc. /de | 7.90M | 6.26% | $36.88M |
| Vanguard group | 4.38M | 6.04% | $8.37M |
| Jpmorgan chase | 3.22M | 3.89% | $7.57M |
| Two sigma investments, lp | 3.04M | 3.66% | $7.98M |
| Citadel advisors | 2.51M | 3.03% | $6.60M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Lynx1 capital management lp | 7.00M | 2.91% | $18.41M |
| Bain capital life sciences investors | 7.17M | 1.70% | $18.86M |
| Soleus capital management | 3.38M | 0.54% | $15.78M |
| Silverarc capital management | 1.91M | 0.51% | $5.03M |
| Verdad advisers, lp | 109.41K | 0.32% | $287.74K |
| Platinum investment management | 384.77K | 0.26% | $1.01M |
| Stempoint capital lp | 453.24K | 0.23% | $1.19M |
| Ra capital management | 8.00M | 0.22% | $21.04M |
| Intrepid family office | 60.00K | 0.13% | $157.80K |
| Wasatch advisors lp | 3.52M | 0.11% | $16.45M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock funding, inc. /de | 7.90M | 0.00% | 5.85M |
| Blackrock | 4.55M | 0.00% | 3.65M |
| Jpmorgan chase | 3.22M | 0.00% | 3.22M |
| Citadel advisors | 2.51M | 0.00% | 2.06M |
| State street | 2.12M | 0.00% | 1.73M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Point72 asset management | 169.10K | 0.00% | -9.27M |
| Commodore capital lp | - | - | -3.41M |
| Samlyn capital | - | - | -3.02M |
| Tcg crossover management | - | - | -1.28M |
| Orbimed advisors | 856.35K | 0.04% | -548.55K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vanguard fiduciary trust | 484.13K | 0.00% | 484.13K | $1.27M |
| Nuveen | 484.01K | 0.00% | 484.01K | $2.26M |
| Stempoint capital lp | 453.24K | 0.23% | 453.24K | $1.19M |
| Platinum investment management | 384.77K | 0.26% | 384.77K | $1.01M |
| Bank of new york mellon | 249.52K | 0.00% | 249.52K | $1.17M |
Sold Out
| Holder | Change |
|---|---|
| Ifp advisors | -17.00 |
| Gradient investments | -25.00 |
| True wealth design | -31.00 |
| Coldstream capital management | -52.00 |
| Capital performance advisors llp | -54.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 106 | -1.85% | 57,677,977 | -27.75% | 69 | 0.57% | 61 | -6.15% | 25 | 8.70% |
| Dec 31, 2025 | 18 | -82.52% | 4,929,202 | -90.62% | 6 | 0.12% | 9 | -82.35% | 6 | -82.86% |
| Sep 30, 2025 | 21 | -78.79% | 4,095,962 | -91.57% | 5 | 0.12% | 9 | -83.33% | 9 | -72.73% |
| Jun 30, 2025 | 100 | -13.04% | 54,689,267 | -14.68% | 77 | 0.90% | 55 | -19.12% | 33 | 17.86% |
| Mar 31, 2025 | 6 | -95.20% | 21,025,800 | -67.35% | 30 | 0.35% | 4 | -93.85% | 1 | -96.97% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 2.14M | 3.01% | - |
| Vanguard Morn Total Stk Mkt Idx Investor | 3.26M | 2.95% | 372.50K |
| Vanguard Total Stock Mkt Idx Inv | 3.26M | 2.95% | 372.50K |
| iShares Russell 2000 ETF | 2.54M | 2.30% | -45.12K |
| Wasatch Ultra Growth | 2.50M | 2.26% | -145.54K |
| SPDR® S&P Biotech ETF | 1.57M | 2.22% | 22.34K |
| Biotech Growth Ord | 1.10M | 1.00% | 889.80K |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.05M | 0.95% | 150.44K |
| Fidelity Small Cap Index | 623.59K | 0.88% | -8.75K |
| Fidelity Enhanced Small Cap Core ETF | 952.32K | 0.86% | 3.67K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Jan 16, 2026 | REYNO LEONARD | Chief Medical Officer | Sell | $22.20K |
| Feb 18, 2025 | Boyle Scott N | Chief Business Officer | Sell | $2.11K |
| Feb 14, 2025 | Boyle Scott N | Chief Business Officer | Sell | $1.54K |
| Feb 08, 2023 | Koppikar Utpal | - | Buy | $31.74K |
| Apr 12, 2022 | Hirsch Andrew | President & CEO | Buy | $84.00K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | - |
| 2026 Q2 | - | - |
| 2026 Q1 | - | 1 |
| 2025 Q4 | - | - |
| 2025 Q3 | - | - |
CCCC Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools